Bristol-Myers Squibb Co. (BMS) said that it has entered into a $1 billion deal with Danish biotechnology company Bavarian Nordic for rights to a late-stage prostate cancer vaccine. The companies entered into an agreement that provides BMS an exclusive option to license and commercialize Prostvac, Bavarian Nordic’s investigational Phase III …